ORGANON & COOO

ORGANON & CO

309.00MXND
−21.11−6.39%
At close at Feb 18, 14:30 GMT
MXN
No trades
See on Supercharts

OGN fundamentals

Key facts

Market capitalization‪79.55 B‬MXN
Founded2020
CEOKevin Ali
About

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Ownership
‪‪257.54 M‬‬
Free Float shares
‪‪256.98 M‬‬ (99.78%)
Closely held shares
‪‪559.38 K‬‬ (0.22%)
Free Float shares
‪‪256.98 M‬‬ (99.78%)
Closely held shares
‪‪559.38 K‬‬ (0.22%)
Capital structure
Market cap
‪‪79.55 B‬‬
Debt
‪‪185.56 B‬‬
Cash & equivalents
‪‪14.07 B‬‬
Enterprise value
‪‪251.04 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪79.55 B‬‬
Price to earning ratio (P/E)
4.87x
Price to sales ratio (P/S)
0.66x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
4.87x
Price to sales ratio (P/S)
0.66x
Valuation ratios
‪0.00‬
‪0.22‬
‪0.44‬
‪0.66‬
‪0.88‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪6.5%‬
‪13.5%‬
‪20.5%‬
‪27.5%‬
‪34.5%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Other
Women's Health - Nexplanon/Implanon NXT
Cardiovascular - Atozet
Respiratory - Singulair
Other - Other
Cardiovascular - Zetia
Cardiovascular - Cozaar/Hyzaar
Biosimilars - Renflexis
Other Non-opioid Pain, Bone and Dermatology
Women's Health - Follistim AQ
By country
Period: 2024
Europe and Canada
United States
Asia Pacific and Japan
Latin America, Middle East, Russia and Africa
China
Global

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Actual
Estimate
Earnings
Next:May 1, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪6.00‬
‪12.00‬
‪18.00‬
‪24.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
33.59%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
7.43%
Last payment
5.737
Last ex-date
Feb 24, 2025
Dividend history
‪1.5%‬
‪3.1%‬
‪4.7%‬
‪6.3%‬
‪7.9%‬
2020
2021
2022
2023
2024
‪0.00‬
‪6.00‬
‪12.00‬
‪18.00‬
‪24.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪50.00 B‬‬
‪‪100.00 B‬‬
‪‪150.00 B‬‬
‪‪200.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
No data available
There's currently no assets and liabilities data to show.